IJNRD Research Journal

WhatsApp
Click Here

WhatsApp editor@ijnrd.org
IJNRD
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)

Call For Paper

For Authors

Forms / Download

Published Issue Details

Editorial Board

Other IMP Links

Facts & Figure

Impact Factor : 8.76

Issue per Year : 12

Volume Published : 9

Issue Published : 94

Article Submitted :

Article Published :

Total Authors :

Total Reviewer :

Total Countries :

Indexing Partner

Join RMS/Earn 300

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Published Paper Details
Paper Title: THE EMERGING ROLE OF TIRZEPATIDE, DUAL GLP-1 AND GIP RECEPTOR AGONIST IN THE MANAGEMENT OF T2DM AND OBESITY: A REVIEW.
Authors Name: Suryawanshi Dipti Madhukar , Dnyaneshwari Bachhav , Kranti Suryawanshi , Niranjan Sonavane , Pooja B. Mairal
Download E-Certificate: Download
Author Reg. ID:
IJNRD_183925
Published Paper Id: IJNRD2211104
Published In: Volume 7 Issue 11, November-2022
DOI:
Abstract: Diabetes mellitus is one of the most common chronic diseases in the country and worldwide, which involves inappropriately increased blood sugar level. Due to its rising prevalence, India faces several challenges in diabetes management. Obesity is another leading risk factor for Type 2 diabetes mellitus (T2DM). There is a strong relation between obesity and diabetes. Having excess body fat is a risk factor for diabetes, and it can also affect a person’s health. To help, manage and potentially prevent diabetes some advanced treatments are needed. Glucagon like peptide 1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) based therapy is the newly established treatment which can helps to minimise glycemic levels, enhance insulin sensitivity and reduce body weight. Tirzepatide, a dual GLP-1/GIP receptor agonist, known as ‘twincretin’, a synthetic peptide analogue of 39 amino acids engineered from the native GIP sequence and contains C20 fatty diacid moiety. Incretin hormones including mainly GLP/GIP-1 are peptides released in the intestine in response to the presence of nutrients in its lumen. They stimulates insulin secretion, inhibits glucagon secretion at pancreatic α cells and also have an effect on extrapancreatic influences as slowing of gastric emptying which increases the feeling of fullness. Tirzepatide could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings. In the present review article, we have made an attempt to explore the characteristics of Tirzepatide including it’s pharmacokinetic and pharmacodynamic activity, structure, synthesis, clinical development in the management of T2DM.
Keywords: Tirzepatide, twincretin, diabetes mellitus, obesity, Incretins, dual agonism
Cite Article: "THE EMERGING ROLE OF TIRZEPATIDE, DUAL GLP-1 AND GIP RECEPTOR AGONIST IN THE MANAGEMENT OF T2DM AND OBESITY: A REVIEW.", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.7, Issue 11, page no.b18-b30, November-2022, Available :http://www.ijnrd.org/papers/IJNRD2211104.pdf
Downloads: 000118744
ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publication Details: Published Paper ID:IJNRD2211104
Registration ID: 183925
Published In: Volume 7 Issue 11, November-2022
DOI (Digital Object Identifier):
Page No: b18-b30
Country: Mungase, Maharashtra, India
Research Area: Pharmacy
Publisher : IJ Publication
Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2211104
Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2211104
Share Article:
Share

Click Here to Download This Article

Article Preview
Click Here to Download This Article

Major Indexing from www.ijnrd.org
Semantic Scholar Microsaoft Academic ORCID Zenodo
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX PUBLON
DRJI SSRN Scribd DocStoc

ISSN Details

ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016

DOI (A digital object identifier)


Providing A digital object identifier by DOI
How to Get DOI? DOI

Conference

Open Access License Policy

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Creative Commons License This material is Open Knowledge This material is Open Data This material is Open Content

Important Details

Social Media

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Join RMS/Earn 300

IJNRD